# Roche Venture Fund

> Roche Venture Fund is a VC fund backing Biotechnology and Health Care. See 120 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Basel, Switzerland
- Total investments: 120
- Last investment: Aug 2026
- Lead investor: 12%
- Last updated: Aug 2026
- X (Twitter): http://twitter.com/roche
- Website: http://www.venturefund.roche.com
- Facebook: http://www.facebook.com/RocheCareers

Roche Venture Fund is a VC fund in Basel focused on Biotechnology and Health Care. The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

## Contacts

5 contacts available for Roche Venture Fund. Shizune tracks 7 team members at Roche Venture Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/roche-venture-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7.5M–$86M |
| Series B | $10M–$125M |
| Series C | $5M–$105M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 55 | 46% |
| Health Care | 34 | 28% |
| Therapeutics | 22 | 18% |
| Medical | 20 | 17% |
| Pharmaceutical | 17 | 14% |

32 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 39 | 33% |
| Series A | 29 | 24% |
| Series C | 16 | 13% |
| Series D | 9 | 8% |
| Funding Round | 7 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 43 | 36% |
| United Kingdom | 4 | 3% |
| Spain | 3 | 3% |
| France | 2 | 2% |
| Switzerland | 2 | 2% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Carole Nuechterlein | Head of Roche Venture Fund | 11 | https://shizune.co/investors/profile/carole-nuechterlein |
| Monique Schiersing | Investment Director | 6 | https://shizune.co/investors/profile/monique-schiersing |
| Simon Greenwood | Investment Director | 2 | https://shizune.co/investors/profile/simon-greenwood |
| Simon Meier | Investment Director | 0 | https://shizune.co/investors/profile/simon-meier |
| Nisha Marathe | Investment Manager | 2 | https://shizune.co/investors/profile/nisha-marathe |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mironid | Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network. | $46M | Series B | Aug 05, 2026 |  |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M | Series B | Jun 18, 2026 |  |
| MISSION Therapeutics | Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. | $13.3M | Venture - Series Unknown | Oct 15, 2025 |  |
| Splice Bio | Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M | Series B | Jun 11, 2025 |  |
| GlycoEra | GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M | Series B | May 27, 2025 |  |
| MISSION Therapeutics | Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. | $32.1M | Series D | Mar 14, 2024 |  |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $105M | Series A | Jan 30, 2024 |  |
| GlycoEra | GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. |  | Series A | Jan 05, 2024 |  |
| NMD Pharma | NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $81.4M | Series B | Nov 15, 2023 |  |
| Aligos Therapeutics | Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertisein liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules. | $92M | Post-IPO Equity | Oct 23, 2023 |  |

10 of 120 investments shown.

## Co-investors
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 19 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 14 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 14 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 13 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 12 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 11 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Speedinvest](https://shizune.co/investors/profile/speedinvest) — VC Fund
- [tecnet equity](https://shizune.co/investors/profile/tecnet-equity) — VC Fund
- [aws Gründungsfonds](https://shizune.co/investors/profile/aws-grnderfonds) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [Life Science VC Funds](https://shizune.co/investors/life-science-vc-funds)

## FAQ

### What does Roche Venture Fund invest in?

Roche Venture Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 120 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Roche Venture Fund's check size?

Roche Venture Fund typically joins rounds of $7.5M–$86M at Series A, $10M–$125M at Series B and $5M–$105M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Roche Venture Fund participates in.

### How do I contact Roche Venture Fund?

Public channels for Roche Venture Fund include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Roche Venture Fund?

The team at Roche Venture Fund includes Carole Nuechterlein (Head of Roche Venture Fund), Monique Schiersing (Investment Director) and Simon Greenwood (Investment Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co